LATEST
GTCR agreed to acquire CCC Intelligent SolutionsnewEQT agreed to acquire StockbridgenewProofpoint agreed to acquire VaronisnewPyrophyte Acquisition . II / SakuuMotown Acquisition agreed to acquire Penske Automotive GroupVivos Therapeutics / SOD SciencesAtlasClear Holdings agreed to acquire Ark Financial ServicesLaboratory of America Holdings / BioReference HealthMubadala Capital acquired Clear Channel OutdoorIthaca Holdings agreed to acquire BumblePenta Fine Ingredients acquired SynerzineHexagon agreed to acquire Rocscience
Open App
ClosedPublished 11 Jun 2026

Chiesi Farmaceutici S.p.A. /
KalVista Pharmaceuticals, Inc.

Chiesi completes acquisition of KalVista Pharmaceuticals

Buy side: Chiesi Farmaceutici S.p.A.
Buy sideChiesi Farmaceutici S.p.A.
Target: KalVista Pharmaceuticals, Inc.
TargetKalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. · 11 Jun 2026Source
See the source
Follow Chiesi Farmaceutici S.p.A. Follow KalVista Pharmaceuticals, Inc.
Buy side: Chiesi Farmaceutici S.p.A.
Buy sideChiesi Farmaceutici S.p.A.
Target: KalVista Pharmaceuticals, Inc.
TargetKalVista Pharmaceuticals, Inc.
01 / BuyerChiesi Farmaceutici S.p.A.
02 / TargetKalVista Pharmaceuticals, Inc.
Source for the buyer and target: KalVista Pharmaceuticals, Inc.

For the buyer and target.

“On April 29, 2026, we previously reported with the U.S. Securities and Exchange Commission (the “SEC”) that KalVista Pharmaceuticals, Inc., a Delaware corporation (“ us ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), dated April 29, 2026, with Chiesi Farmaceutici S.p.A., an Italian società per azioni (“ Parent ”), Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”) and KalVista Pharmaceuticals Limited, a private limited company organized under the laws of England and Wales.”

Published 11 Jun 2026

Open the source
01

What happened

Chiesi Farmaceutici has finished its takeover of KalVista Pharmaceuticals through a tender offer followed by a merger. KalVista is now a wholly owned subsidiary of Chiesi, and its shares stopped trading on the Nasdaq Global Market before the market opened on June 11, 2026. [01]

The merger was completed without a stockholder vote, and the remaining shares were converted into the right to receive the $27.00 offer price in cash. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · KalVista Pharmaceuticals, Inc.

Chiesi completes acquisition of KalVista Pharmaceuticals

This document is the source for the companies, stage and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Also stated

    “KalVista is now a wholly owned subsidiary of Chiesi, and its shares stopped trading on the Nasdaq Global Market before the market opened on June 11, 2026”

    Open the source

  2. Published by KalVista Pharmaceuticals, Inc.

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.

04

Deal Web

Every firm and person on this deal, and how they connect. Open any name to see their other deals.

Deal Web · 2 firms · 0 peopleHover a name to see how it connects
This dealChiesi Farmaceutici S.p.A. / KalVista Pharmaceuticals, Inc.Closed · Published 11 Jun 2026
BuyerChiesi Farmaceutici S.p.A.TargetKalVista Pharmaceuticals, Inc.
This dealChiesi Farmaceutici S.p.A. / KalVista Pharmaceuticals, Inc.

Closed · Chiesi Farmaceutici S.p.A. / KalVista Pharmaceuticals, Inc. deal (Closed, published 11 Jun 2026).

Published 11 Jun 2026
Timeline
  1. Also stated
  2. Published by KalVista Pharmaceuticals, Inc.
Hover or tap a name to see how it connects, and when
Deal Web as a list